At Vertex, we are relentless in our pursuit of transformative medicines to improve the lives of people with serious diseases. Building on a strong foundation of advancing therapies for cystic fibrosis, Vertex continues to expand its leadership across multiple disease areas, including cell and gene therapies, with the goal of delivering meaningful impact for patients worldwide.
Our Global Heme Cell and Gene Therapy (CGT) Operations team is at the forefront of innovation, commercial strategy, and operational excellence, driving the evolution of the global, cross-functional, "vein to vein” business process for CASGEVY, the only CRISPR-based autologous gene therapy approved for people living with Sickle Cell Disease and Transfusion dependent beta thalassemia.
We are seeking an Associate Director, Heme CGT Business Systems to lead global system strategy for CASGEVY. This critical role will be responsible for owning the strategy, roadmap and execution of the order management system and key commercial tools and processes, essential to delivering a vein-to-vein, autologous product. As CASGEVY continues to scale across 9+ markets globally, the successful candidate will bring a strategic, analytical, and collaborative mindset, provide cross-functional leadership and drive alignment among international and US Heme Business Units, Manufacturing, Quality, and Technology teams involved in CASGEVY delivery.
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and has made significant advancements in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, and acute pain — and continues to progress clinical and research programs in these diseases. We also have a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where we have deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Our global headquarters is in Boston, and we have research and development (R&D) sites and commercial offices worldwide. Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. We have also earned a spot on TIME Most Influential Companies, TIME Best Inventions, and Fast Company Most Innovative Companies lists. Our research and medicines have received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the Prix Galien, the Scrip Award and the Breakthrough Prize awards. Read our community guidelines: https://www.vrtx.com/vertexs-community-guidelines/
View company profile →